Erin Whitney as head of global clinical operations and
Keith White as head of global market access and has also appointed brand strategy consultant
Shauna Horvath to head of global marketing. Whitney joins the team from bluebird bio, while Merck and Genentech veteran White was most recently VP, global market access and pricing at Corbus Pharmaceuticals. Horvath joined Amylyx as a consultant in 2019.
> Culver City, California’s ImmunityBio tapped
Fabio M. Benedetti, M.D., as chief strategy officer, effective Jan. 4. Should ImmunityBio’s NantKwest merger close, Benedetti is expected to assume the role of CSO at the combined company, ImmunityBio said. Benedetti joins from combination therapy specialist Apollomics, where he was chief medical officer.
Published: Jan 01, 2021 By Alex Keown
ImmunityBio – Fabio M. Benedetti was named chief strategy officer of California-based ImmunityBio. Benedetti will oversee life-cycle management, pipeline and commercial strategy, including medical affairs. Following the completion of ImmunityBio’s
proposed merger with NantKwest, Benedetti is expected to assume the role of chief strategy officer of the combined company. Benedetti most recently served as chief medical officer for Apollomics, Inc., where he led global clinical development programs including clinical strategy, clinical development, and regulatory affairs. He also previously served as Global CMO at Taiho Pharmaceutical Company, Ltd. and CMO for Taiho Oncology, Inc. Prior to Taiho, he held the positions of senior vice president of Clinical Oncology and CMO at Geron Corporation. He also held roles at Onyx Pharmaceuticals, Millennium Pharmaceuticals, Roche and Bristol-Myers Squibb.